批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
>>>原始批准或临时批准<<<
| 审批日期 | 提交号 | 审批结论 | 提交分类 | 审评优先级;罕用药状态 | 通知信、审评文件、说明书、包装标签 | 备注 |
| 2013/02/26 |
ORIG-1(原始申请) |
Approval |
Type 1 - New Molecular Entity |
STANDARD
|
|
|
>>>补充申请<<<
| 审批日期 | 提交号 | 审批结论 | 补充类别或审批类型 | 审评优先级;罕用药状态 | 通知信、审评文件、说明书、包装标签 | 备注 |
| 2025/02/07 |
SUPPL-18(补充) |
Approval |
Labeling-Package Insert |
STANDARD
|
|
|
| 2024/02/15 |
SUPPL-22(补充) |
Approval |
Labeling-Package Insert |
STANDARD
|
|
|
| 2019/01/25 |
SUPPL-15(补充) |
Approval |
Efficacy-New Indication |
STANDARD
|
|
|
| 2018/10/26 |
SUPPL-14(补充) |
Approval |
Labeling-Package Insert |
STANDARD
|
|
|
| 2017/03/17 |
SUPPL-12(补充) |
Approval |
Manufacturing (CMC)-Control |
N/A
|
|
|
| 2016/11/03 |
SUPPL-11(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
| 2015/08/24 |
SUPPL-10(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
| 2015/08/24 |
SUPPL-9(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
| 2015/08/24 |
SUPPL-8(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
| 2015/04/23 |
SUPPL-6(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
| 2015/04/20 |
SUPPL-7(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
| 2015/02/25 |
SUPPL-5(补充) |
Approval |
Labeling-Package Insert |
STANDARD
|
|
|
| 2014/05/02 |
SUPPL-4(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
| 2014/01/08 |
SUPPL-3(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
| 2013/09/27 |
SUPPL-2(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
| 2013/08/13 |
SUPPL-1(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
与本品相关的专利信息(来自FDA橙皮书Orange Book)
与本品治疗等效的药品
>>>活性成分:OSPEMIFENE; 剂型/给药途径:TABLET;ORAL; 规格:60MG; 治疗等效代码:AB<<<
| 申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
| 203505 |
001 |
NDA |
OSPHENA |
OSPEMIFENE |
TABLET;ORAL |
60MG |
Prescription |
Yes |
Yes |
AB |
2013/02/26
|
DUCHESNAY |
| 215574 |
001 |
ANDA |
OSPEMIFENE |
OSPEMIFENE |
TABLET;ORAL |
60MG |
Discontinued |
No |
No |
AB |
2024/02/13
|
HETERO LABS LTD V |